• For Institutions

  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Nov25
Inhibrx Biosciences Reports Q3 2025 Earnings and ozekibart Clinical Trial Progress
04:12
Nov15
Inhibrx Biosciences released FY2025 9 Months Earnings on November 14, 2025 (EST), with actual revenue of USD 1.3 M and EPS of USD -6.9325
04:00
Inhibrx Biosciences released FY2025 Q3 earnings on November 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.28 (forecast USD -1.72)
04:00
Nov14
Inhibrx Biosciences Inc. Reports Q3 2025 Loss and Publishes ozekibart Trial Results
11:00
Nov4
Inhibrx Biosciences Inc. Announces Positive Phase 2 Results for Ozekibart (INBRX-109) in Chondrosarcoma
21:02
Oct30
Inhibrx Reports Positive Phase 2 Results for Ozekibart in Advanced Chondrosarcoma
22:44

Schedules & Filings

Schedules
Filings
Nov14
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -35.26 M, EPS -2.28

Aug13
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 1.3 M, Net Income -28.65 M, EPS -1.8524

May14
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -43.31 M, EPS -2.8

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
BBGI
19.800
+388.89%
+15.750
SRV.RT
0.1426
+235.53%
+0.100
ASPC
24.410
+132.92%
+13.930
ENVB
10.136
+71.22%
+4.210
BEAT
1.310
+62.63%
+0.494
GRAN
3.700
+54.17%
+1.300
BDRX
6.226
+52.98%
+2.156
CGTL
0.9707
+47.10%
+0.318
PLAB
37.280
+45.12%
+11.590
HSPOR
0.1290
+43.17%
+0.039
View More